Management of Chronic Leukopenia

Diagnostic Evaluation and Risk Stratification

The American College of Hematology recommends evaluating for bi- or pancytopenia, which suggests bone marrow production failure and mandates bone marrow aspirate and biopsy, as this distinguishes between production defects, infiltrative processes, and peripheral destruction 1
The American Society of Clinical Oncology suggests obtaining bone marrow aspirate and biopsy when pancytopenia is present or when the etiology remains unclear 1

The National Comprehensive Cancer Network recommends initiating disease-directed therapy when cytopenias are caused by marrow infiltration (hemoglobin <100 g/L or platelets <100 × 10⁹/L) 1
The European Society for Medical Oncology suggests obtaining FISH for del(17p) and TP53 mutation status before treatment, as these predict poor response to conventional chemotherapy 1
For chronic lymphocytic leukemia with cytopenias, the International Workshop on Chronic Lymphocytic Leukemia recommends fludarabine-based regimens or rituximab-containing chemoimmunotherapy for fit patients 1
The American Society of Hematology recommends controlling active infections before initiating purine analog therapy, as these agents cause profound immunosuppression lasting >12 months 1
The European Hematology Association suggests initiating corticosteroids as first-line therapy when Coombs test or platelet-associated immunoglobulin testing confirms autoimmune etiology 1

The National Cancer Institute recommends holding TKI therapy when ANC <1.0 × 10⁹/L and/or platelets <50 × 10⁹/L, and resuming at starting dose once ANC ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L 2
The European Society for Medical Oncology suggests monitoring blood counts weekly during the first 4-6 weeks, then every 2 weeks until month 3, then every 3 months 2, 3
The American Society of Clinical Oncology recommends avoiding empiric antibiotic prophylaxis in chronic stable neutropenia without fever, as universal prophylaxis is not warranted 4

The American College of Physicians recommends monitoring CBC every 3 months for stable, asymptomatic chronic leukopenia 5

The American Society of Clinical Oncology recommends that most patients with autoimmune hemolytic anemia (AIHA) respond to corticosteroids 6
For corticosteroid-refractory cases, consider rituximab alone or combined with cyclophosphamide and dexamethasone, or bendamustine plus rituximab, as suggested by the European Society for Medical Oncology 7
In patients with resistant autoimmune cytopenia, treat the underlying CLL before considering splenectomy, according to the National Comprehensive Cancer Network 7
Note that up to 40% of immune checkpoint inhibitor-related AIHA may have negative Coombs testing, as reported by the American Society of Clinical Oncology 8

The Infectious Diseases Society of America recommends that antibiotic and antiviral prophylaxis should only be used in patients with recurrent infections and/or very high risk (e.g., pneumocystis prophylaxis with co-trimoxazole during purine analogue therapy or idelalisib) 6, 7
Prophylactic intravenous immunoglobulin does NOT impact overall survival and is only recommended in patients with severe hypogammaglobulinemia and repeated or severe infections, as suggested by the International Immunoglobulin Society 6, 7
The Centers for Disease Control and Prevention recommend that pneumococcal vaccination and seasonal flu vaccination should be administered in early-stage CLL 7